Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XACT-LUNG: Ascorbate with Chemoradiotherapy for NSCLC
NCT02905591Phase 2Active, not recruiting
- Start
- Nov 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascorbic acid in non-small cell lung cancer (NSCLC). Primary endpoint: Progression Rate at the Completion of Radiation and Chemotherapy. Started Nov 2018; status: active, not recruiting.
02
Drugs
ascorbic acid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02905591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905591.